|
Market Closed -
Nasdaq
16:00:00 2026-08-31 EDT
|
5-day change | 1st Jan Change | ||
| 1.220 USD | +1.67% |
|
+0.41% | -47.64% |
| 08-12 | Spero Therapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026 | |
| 08-12 | Spero Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Company Valuation: Spero Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 517.5 | 89.57 | 77.91 | 56.15 | 131.3 | 69.88 | - |
| Change | - | -82.69% | -13.02% | -27.92% | 133.77% | -46.77% | - |
| Enterprise Value (EV) | 371.1 | 89.57 | 77.91 | 56.15 | 131.3 | 69.88 | 69.88 |
| Change | - | -75.86% | -13.02% | -27.92% | 133.77% | -46.77% | 0% |
| P/E | -5.5x | -1.41x | 3.42x | -0.81x | 15.5x | -4.14x | 1.79x |
| PBR | - | - | - | - | - | - | - |
| PEG | - | 0x | -0x | 0x | -0x | 0x | -0x |
| Capitalization / Revenue | 28,346,906x | 1,673,972x | 750,706x | 1,170,430x | - | - | - |
| EV / Revenue | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - |
| EV / EBIT | - | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -2.91 | -1.23 | 0.43 | -1.27 | 0.15 | -0.29 | 0.67 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales | 18.26 | 53.51 | 103.8 | 47.98 | - | - | - |
| EBITDA | -87.32 | - | - | - | - | - | - |
| EBIT | -87.97 | -42.2 | 21.48 | -73.36 | - | - | - |
| Net income | -89.76 | -46.42 | 22.81 | -68.57 | - | - | - |
| Net Debt | -146.4 | - | - | - | - | - | - |
| Reference price 2 | 16.010 | 1.730 | 1.470 | 1.030 | 2.330 | 1.200 | 1.200 |
| Nbr of stocks (in thousands) | 32,324 | 51,776 | 52,999 | 54,518 | 56,339 | 58,235 | - |
| Announcement Date | 3/31/22 | 3/30/23 | 3/13/24 | 3/27/25 | 3/26/26 | - | - |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.14x | - | - | - | 69.88M | |
| 20.59x | 7.25x | 14.66x | 1.42% | 69.54B | |
| 36.89x | 9.62x | 29.41x | 0.04% | 64.97B | |
| 30.69x | 6.58x | 17.2x | -.--% | 26.51B | |
| -72.56x | 13.98x | -67.43x | -.--% | 25.89B | |
| -15.61x | 5.94x | -7.46x | -.--% | 25.64B | |
| 58.27x | 21.67x | 43.95x | 0.26% | 20.22B | |
| 27.27x | 5.11x | 16.98x | -.--% | 19.98B | |
| 1415.29x | 39.34x | 858.54x | -.--% | 15.69B | |
| 16.84x | 5x | 11.66x | -.--% | 13.49B | |
| Average | 151.35x | 12.72x | 101.95x | 0.19% | 28.2B | |
| Weighted average by Cap. | 94.02x | 10.79x | 57.82x | 0.38% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SPRO Stock
- Valuation Spero Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
